<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084783</url>
  </required_header>
  <id_info>
    <org_study_id>38RC16.015</org_study_id>
    <nct_id>NCT03084783</nct_id>
  </id_info>
  <brief_title>Dexamethasone in Herpes Simplex Virus Encephalitis</brief_title>
  <acronym>DexEnceph</acronym>
  <official_title>Dexamethasone in Herpes Simplex Virus Encephalitis : a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Encephalitics is a serious condition in which the brain becomes inflamed (swollen). It
      usually happens as a direct result of virus, such as herpes simplex virus (HSV).

      HSV encephalitis is often treated with the drug acyclovir (an antiviral drug which slows the
      growth and spread of HSV in the body). Despite this however, around 2 out of every 3 people
      will have memory difficulties long term. Dexamethasone is a corticosteroid medication, which
      works by preventing the release of natural chemicals in the body which cause inflammation. It
      is possible that dexamethasone could help to reduce in swelling of the brain may improve the
      recovery of patients with HSV encephalitis. The aim of this study is to find out whether
      treatment with dexamethasone can improve long-term health outcomes in adults with HSV
      Encephalitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Calcul of verbal memory score</measure>
    <time_frame>at 6 months post randomization</time_frame>
    <description>The primary outcome is a verbal memory score as determined by the Wechsler Memory Scale (WMS-IV) Auditory Memory Index, at 6 months post randomisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Memory Index assessed by the Wechsler Memory Scale</measure>
    <time_frame>6 months and 18 months post randomization</time_frame>
    <description>Neuropsychological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Processing Working Memory - assessed by the Wechsler Adult Intelligence Scale version IV</measure>
    <time_frame>6 months and 18 months post randomization</time_frame>
    <description>Neuropsychological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Language -assessed by the confrontational naming task of the Language Module in the Neuropsychology Assessment Battery</measure>
    <time_frame>6 months and 18 months post randomization</time_frame>
    <description>Neuropsychological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Higher executive function -assessed by Trail Making Test Parts A and B</measure>
    <time_frame>6 months and 18 months post randomization</time_frame>
    <description>Neuropsychological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premorbid cognitive ability - assessed by the Test of Premorbid Function (TOPF);</measure>
    <time_frame>6 months and 18 months post randomization</time_frame>
    <description>Neuropsychological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety -assessed by self-completed Beck Anxiety Inventory</measure>
    <time_frame>6 months and 18 months post randomization</time_frame>
    <description>Neuropsychological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression -assessed by self-completed Beck Depression Inventory Inventory</measure>
    <time_frame>6 months and 18 months post randomization</time_frame>
    <description>Neuropsychological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7. Participant's subjective cognitive complaints- assessed by the Perceived Deficits Questionnaire</measure>
    <time_frame>6 months and 18 months post randomization</time_frame>
    <description>Neuropsychological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Assessment assessed by Addenbrooke's Cognitive Assessment revised (ACE-III)</measure>
    <time_frame>at 30 days/discharge, 6 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of intensive care or high dependency admission</measure>
    <time_frame>during 18 months</time_frame>
    <description>clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of Glasgow Coma Scale (GCS)</measure>
    <time_frame>during 18 months</time_frame>
    <description>clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of epilepsy</measure>
    <time_frame>during 18 months</time_frame>
    <description>clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of temporal lobe volume (as % of intra-cranial volume)</measure>
    <time_frame>Baseline, 2 weeks, 6 months and 18 months</time_frame>
    <description>Imaging Outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Whole brain volume (as % of intra-cranial volume)</measure>
    <time_frame>Baseline, 2 weeks, 6 months and 18 months</time_frame>
    <description>Imaging Outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic and proteomic profiling on CSF</measure>
    <time_frame>at baseline and 2 weeks</time_frame>
    <description>Biomarker outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic and proteomic profiling on blood</measure>
    <time_frame>at baseline, 4 days, 2 weeks, and 6 months</time_frame>
    <description>Biomarker outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti NMDA receptor antibody testing</measure>
    <time_frame>at 6 months</time_frame>
    <description>Biomarker outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with detectable HSV in CSF</measure>
    <time_frame>at 2 weeks</time_frame>
    <description>Safety Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell function</measure>
    <time_frame>at 4 days and 6 months</time_frame>
    <description>Safety Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status Measured by the EuroQOL-5D-5Lquestionnaire</measure>
    <time_frame>at 6 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured by SF-36 questionnaires</measure>
    <time_frame>at 6 and 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HSV Encephalitis</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants receive standard care and no dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Suspected encephalitis criteria:

             Acute or subacute (up to 4 weeks) alteration in consciousness, cognition, personality
             or behaviour* persisting for &gt; 24 hours.

          2. Laboratory confirmed HSV by positive PCR on CSF sample.

          3. Receiving intravenous aciclovir dosed at 10mg/kg TDS or at a reduced dose in renal
             impairment

          4. Age â‰¥ 186 years

          5. Written informed consent has been given by the patient or their legal representative

        Exclusion Criteria:

          1. Currently receiving oral or injectable corticosteroid therapy; including treatment
             with oral or injectable corticosteroids in the last 30 days.

          2. History of hypersensitivity to corticosteroids

          3. Immunosuppression secondary to:

               1. Known HIV infection &amp; CD4 count under 200cell/mm3

               2. Biologic therapy or other immunosuppressive agents [azathioprine, methotrexate,
                  ciclosporin]

               3. Solid organ transplant on immunosuppression

               4. Bone marrow transplant

               5. Currently undergoing a course of chemotherapy or radiotherapy

               6. Known immunodeficiency syndrome [other than HIV]

               7. Known haematological malignancy

          4. Pre-existing indwelling ventricular devices

          5. Peptic ulcer disease in the last 6 months: defined as a peptic ulcer seen at previous
             endoscopy or an upper gastrointestinal bleed causing â‰¥ 2 unit haemoglobin drop

          6. Currently on an antiretroviral regime containing rilpivirine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul STAHL</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Paul STAHL</last_name>
    <phone>04 76 76 68 13</phone>
    <email>jpstahl@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AnaÃ¯s ADOLLE</last_name>
    <email>aadolle@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HÃ´pital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU HÃ´tel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Bichat-Claude Bernard, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes, HÃ´pital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Delafontaine</name>
      <address>
        <city>Saint-Denis</city>
        <zip>93205</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy, Hopitaux de Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res. 2006 Sep;71(2-3):141-8. Epub 2006 Apr 25. Review.</citation>
    <PMID>16675036</PMID>
  </reference>
  <reference>
    <citation>Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, Cunningham R, Zuckerman M, Mutton KJ, Solomon T, Ward KN, Lunn MP, Irani SR, Vincent A, Brown DW, Crowcroft NS; UK Health Protection Agency (HPA) Aetiology of Encephalitis Study Group. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010 Dec;10(12):835-44. doi: 10.1016/S1473-3099(10)70222-X. Epub 2010 Oct 15. Erratum in: Lancet Infect Dis. 2011 Feb;11(2):79.</citation>
    <PMID>20952256</PMID>
  </reference>
  <reference>
    <citation>Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, Hartman BJ, Kaplan SL, Scheld WM, Whitley RJ; Infectious Diseases Society of America. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008 Aug 1;47(3):303-27. doi: 10.1086/589747.</citation>
    <PMID>18582201</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dexamethasone</keyword>
  <keyword>HSV encephalitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Encephalitis, Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

